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Introduction: Small increases in mean serum creatinine (SCr) were observed in studies of rheumatoid arthritis
patients during tofacitinib treatment. These SCr changes were investigated and potential mechanisms explored.
Methods: SCr values and renal adverse event data were pooled from five Phase 3 and two long-term extension
(LTE) studies. Dose-response relationships and association with inflammation (C-reactive protein (CRP)) were
explored using Phase 2 data and confirmed with Phase 3 data.
Results: In Phase 3, least squares mean SCr differences from placebo at Month 3 were 0.02 and 0.04 mg/dl for
tofacitinib 5 and 10 mg twice daily (BID) (P <0.05), respectively. During Months 0 to 3, confirmed SCr ≥33% increases
over baseline were reported in 17 (1.4%; 5 mg BID) and 23 (1.9%; 10 mg BID) patients. Generally, elevations plateaued
and remained within normal limits throughout Phase 3 and LTE studies. Exposure-response modeling demonstrated
small, reversible effects of tofacitinib on mean SCr, and significant (P <0.05) effects of CRP on model parameters.
Phase 3 data confirmed that patients with higher baseline CRP or greater CRP decreases following tofacitinib treatment
had the largest increases in SCr. Across Phase 3 and LTE studies, 22 tofacitinib-treated patients had clinical acute renal
failure (ARF), predominantly in the setting of concurrent serious illness.
Conclusions: Tofacitinib treatment was associated with small, reversible mean increases in SCr that plateaued early.
The mechanism behind these SCr changes remains unknown, but may involve effects of tofacitinib on inflammation.
ARF occurred infrequently, was associated with concurrent serious illness, and was unrelated to prior SCr increases.Introduction
Tofacitinib is an oral Janus kinase (JAK) inhibitor for the
treatment of rheumatoid arthritis (RA). It is a selective in-
hibitor of the JAK family and blocks intracellular signaling
of multiple key cytokines involved in the inflammatory
cascade [1].
Six Phase 3 studies of tofacitinib in several RA patient
populations have been completed. Tofacitinib dosed 5 and
10 mg twice daily (BID), as monotherapy or in combin-
ation with nonbiologic disease-modifying anti-rheumatic
drugs (DMARDs), was efficacious, providing benefits in
the signs and symptoms of RA, structural preservation,
and in physical function and patient-reported outcomes.* Correspondence: chudi.i.nduaka@pfizer.com
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stated.The safety profile of tofacitinib was consistent across the
studies [2-7].
During the tofacitinib RA clinical development program,
increases in mean serum creatinine (SCr) were observed
in patients, despite lack of nephrotoxicity in preclinical
and healthy volunteer studies [8-10]. Although SCr is
widely used as an indicator of glomerular filtration rate
(GFR) and therefore renal function, a number of factors
may influence its generation and clearance for example,
glomerular filtration of creatinine, muscle mass and turn-
over [11-13].
The objectives of this report are to investigate the clin-
ical significance of these changes in SCr in the RA popu-
lation and to address potential mechanisms.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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SCr values and renal adverse event (AE) data were pooled
from five Phase 3 studies (in DMARD-inadequate re-
sponders) and two ongoing long-term extension (LTE)
studies investigating tofacitinib (CP-690,550; Pfizer Inc,
Groton, CT, USA) in RA. Evaluation of exposure-response
relationships and covariate analyses were performed on
five Phase 2 studies using nonlinear mixed-effects models.
Phase 3 data were used to verify the hypothesis generated
from exposure-response models, with emphasis on the re-
lationship between changes in SCr and C-reactive protein
(CRP), and creatine kinase (CK; small changes in CK were
observed during Phase 3 studies) and CRP.
Clinical studies
Tofacitinib 1, 3, 5, 10, 15, and 30 mg BID or 20 mg once daily
(QD; A3921025 only) was investigated in five Phase 2 ran-
domized, double-blind, placebo-controlled, multicenter stud-
ies (index studies): A3921019 (NCT00147498), A3921035
(NCT00550446), and A3921040 (NCT00687193) were tofa-
citinib monotherapy studies; A3921025 (NCT00413660)
and A3921039 (NCT00603512) included background
methotrexate (MTX). A3921035 included a monotherapy
adalimumab arm as an active control. Details of individual
study designs have been published previously [14-18].
The Phase 3 studies were double-blind, placebo-controlled,
global studies (index studies): ORAL Step (A3921032;
NCT00960440), ORAL Scan (A3921044; NCT00847613),
ORAL Solo (A3921045; NCT00814307), ORAL Sync
(A3921046; NCT00856544), and ORAL Standard (A3921064;
NCT00853385). Tofacitinib 5 or 10 mg BID was investi-
gated alone or in combination with nonbiologic DMARDs,
mainly MTX, in several populations of RA patients who
had previously demonstrated an inadequate response to at
least one nonbiologic or biologic DMARD. ORAL Stand-
ard included an adalimumab plus MTX arm as an active
control. In studies of ≥6 months’ duration, placebo patients
who did not achieve a decrease in tender and swollen
joints of at least 20% were advanced to tofacitinib at
Month 3. All remaining placebo patients advanced to
tofacitinib at Month 6. In the shorter studies, all pla-
cebo patients were advanced to tofacitinib at Month 3.
Details of individual study designs have been published
previously [2-6].
Patients from the Phase 2 and Phase 3 index studies
could participate in one of two open-label, LTE studies.
A3921024 (NCT00413699) included patients outside
Japan. A3921041 (NCT00661661) was a multicenter study
of Japanese patients from the Phase 2 (A3921039 or
A3921040) and Phase 3 (ORAL Scan) studies. Upon LTE
study entry, patients from Phase 2 received 5 mg BID and
patients from Phase 3 received 10 mg BID, with the excep-
tion of Chinese and Japanese patients in Phase 3 studies
who received 5 mg BID. Dose adjustments, as well asadjustments of concomitant medications, were permitted
in the LTE studies [19]. LTE data collection and analyses
are still ongoing; therefore, some values may change for
the final analyses.
Full inclusion and exclusion criteria can be found
in the individual study publications. Briefly, across
Phases 2 and 3, patients were aged ≥18 years (≥20 years in
Japan) with a diagnosis of moderate to severe active RA
for ≥6 months and met American College of Rheuma-
tology 1987 revised classification criteria [20]. Exclu-
sion criteria relevant to the current analyses included:
GFR ≤60 ml/min (the Cockcroft-Gault calculation) for
A3921019, GFR ≤50 ml/min for the remaining Phase 2
studies, and GFR ≤40 ml/min for the five Phase 3 studies;
or current or recent history of uncontrolled clinically sig-
nificant renal disease.
Data presented in this study were taken from five
Phase 2, five Phase 3 and two LTE studies. All studies were
conducted in compliance with the Declaration of Helsinki,
International Conference on Harmonisation Good Clinical
Practice guidelines, and local country regulations. The final
protocols, any amendments, and informed consent docu-
mentation were reviewed and approved by the Institutional
Review Board and the Independent Ethics Committee of
the investigational centers - see Additional files 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, and 12. All patients provided written
informed consent.
SCr monitoring and discontinuation
For the Phase 2 studies, baseline values were those taken
on Day 0 or Week 0 prior to the first study dose. For the
Phase 3 studies, calculated baseline values were the aver-
age of the screening and baseline values. For the LTE
studies, baseline values were those of the Phase 2 or
Phase 3 study for patients enrolling within 7 (A3921041)
or 14 (A3921024) days of participation; if enrollment
was >7 or >14 days after participation, baseline was the
start of the LTE study prior to the first LTE study dose.
In Phase 2 studies other than A3921019, patients were
withdrawn for SCr increases >50% relative to baseline. In
the Phase 3 and A3921041 LTE studies, patients discontin-
ued therapy if two sequential increases in SCr >50% over
baseline values were reported. Patients with SCr ≥33% at
the end of treatment (EoT) or discontinuation were
followed until SCr levels were within 10% of the baseline/
screening value. In the A3921024 LTE study, for any
SCr increase >50% over baseline values, adjustments
in concomitant medications and/or dose of study drug
were permitted within a 90-day period from the initial
>50% SCr increase. If the >50% increase persisted
for >90 days, the patient was withdrawn. However,
patients were to be withdrawn if they had two se-
quential increases in SCr >100% over baseline values,
irrespective of the 90-day period (protocol-specified).
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ing discontinuation, SCr changes of ≥33% were ana-
lyzed throughout the index study, as well as at the
EoT or discontinuation.Shift analyses
To examine the pattern of longer-term changes, patients
in Phase 3 who continued into the LTE studies were clas-
sified into four categories based on their change from
baseline in SCr at the EoT in the Phase 3 studies: ≤10%,
>10 to <33%, ≥33 to ≤50%, and >50%. Patients in these
four cohorts were followed in the LTE studies and reclas-
sified into the same categories, based on the maximum
percentage increase category achieved in two consecu-
tive SCr measurements. Mean changes in SCr from
baseline to the EoT in the Phase 3 and to the last ob-
served visit (LOV) in the LTE studies were calculated for
each of the four cohorts.Exposure-response analyses
The SCr data were described using a nonlinear mixed-
effects model with multiplicative inter-individual random
effects and an additive residual random effect (measure-
ment error) to characterize the relationship between tofa-
citinib exposure and SCr levels. The structural form of the
model was an indirect response model [21] comprising
the following parameters: baseline (R0), SCr elimination
rate constant (Kout), maximum inhibitory drug effect
(Emax), and the dose that achieves 50% of the maximum
drug effect (ED50). No inference was made with respect to
whether tofacitinib influences the clearance or production
of SCr despite the functional form of the model. An early
dose-ranging Phase 2 study (A3921019) assessed SCr re-
versibility; patients with RA received tofacitinib 5, 15 or
30 mg BID for six weeks, followed by a six-week washout
period, and SCr levels were monitored.
To explore a possible relationship between inflamma-
tion and changes in SCr, the influence of baseline CRP
was estimated on four model parameters: R0, Kout, Emax,
and ED50. Likelihood ratio tests were applied to evaluate
improvement in goodness-of-fit when baseline CRP was
added to the model. All analyses were performed using
the first-order conditional-estimation method as imple-
mented in the NONMEM software (v6, and v7 once
available; ICON Plc, Dublin, Ireland).
Data from Phase 3 studies, not used in the modeling ana-
lysis, were analyzed descriptively by comparing the mean
changes in SCr based on quartiles of baseline CRP, as well
as quartiles of change from baseline in CRP at Week 12.
Small increases in CK were observed in the Phase 3 clinical
program; therefore, a similar analysis was performed for
changes in CK as a function of CRP and for changes in SCr
as a function of changes in CK.Adverse event analysis
AE data from Phase 3 and LTE studies were classified using
the narrow SMQ (Standardized MedDRA (Medical Diction-
ary for Regulatory Activities) Queries) term of acute renal
failure (ARF) and was further narrowed to include all pa-
tients whose AE met one of the following criteria: coded to
the narrow SMQ of ARF (including preferred terms of acute
phosphate nephropathy, acute prerenal failure, anuria, azo-
temia, continuous hemodiafiltration, dialysis, hemodialysis,
nephropathy toxic, oliguria, peritoneal dialysis, renal fail-
ure, renal impairment); required permanent or temporary
discontinuation of the study drug; or required a dose re-
duction of the study drug. This included laboratory investi-
gations (for example, increased blood creatinine) as well as
clinical renal and urinary disorders (for example, protein-
uria, nephritis, renal impairment, ARF) [22]. Patients with
clinical ARF were defined by the MedDRA terms: renal
failure, azotemia, or renal impairment [22].
Patient data were then reviewed (nonblinded) in order to
ascertain a potential etiology (or etiologies) for the renal
AE. Data reviewed included demographics, investigator-
reported term for the event, day of onset, and day of reso-
lution or last evaluation - all relative to the start of the
study drug, SCr, creatinine clearance (the Cockcroft-Gault
calculation), maximum SCr value achieved, tofacitinib
dose, concomitant medications, past medical history, asso-
ciated or concurrent events, action taken, outcome of the
event, and investigator and Pfizer case assessments. The
focus of the concomitant medication review was on those
medications with known associations with changes in renal
function such as angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs), non-
steroidal anti-inflammatory drugs (NSAIDs) (both select-
ive and nonselective cyclooxygenase inhibitors), diuretics,
and nephrotoxic agents.
Results
Across Phase 3, 3,315 patients received ≥1 dose of study
drug (tofacitinib, placebo, or adalimumab) for durations that
ranged up to 474 days. In the LTE studies, as of March 29,
2011, 3,227 patients received ≥1 dose of tofacitinib; of those,
2,019 received tofacitinib with background DMARDs and
1,208 received tofacitinib monotherapy. The Phase 2 model
dataset held 1,475 patients, with 10,343 SCr observations
for placebo and tofacitinib treatments and with a tofacitinib
1 to 30 mg BID dose range up to 24 weeks in duration.
In Phase 2 and 3 studies, patients had a mean age of 50.6
to 53.4 and 52.2 to 53.2 years, respectively; most patients
were female and were Caucasian (with the exception of
A3921039 and A3921040 where all patients were Japanese).
Changes in SCr
Tofacitinib treatment in pooled Phase 3 studies over
12 months resulted in mean increases from baseline in
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antly within the first three months. The least squares
(LS) mean SCr increases at Month 3 were 0.07 and
0.08 mg/dl for 5 and 10 mg BID tofacitinib doses, re-
spectively, compared with 0.04 mg/dl in the placebo andFigure 1 SCr changes in Phase 3 studies. (A) Mean (±SE) change from b
(B) SCr outliers during tofacitinib 5 mg BID treatment. (C) SCr outliers during0.06 mg/dl in the adalimumab groups. The differences
(upper 95% confidence intervals) between the tofacitinib
groups and the placebo group in LS mean increases were
estimated to be 0.02 (0.04) and 0.04 (0.05) mg/dl for the
5 and 10 mg BID groups, respectively.aseline in SCr (mg/dl) across the Phase 3 program (0 to 12 months).
tofacitinib 10 mg BID treatment.
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tients had a confirmed SCr increase of ≥33% from baseline
in Months 0 to 3. Of these, two had a SCr measurement
above the reference range (upper limit of normal: 1.1 and
1.3 mg/dl for females and males, respectively). One patient
discontinued due to increased SCr with subsequent return
to baseline. The second patient discontinued due to an
episode of sepsis (Figure 1B). In the tofacitinib 10 mg BID
group, 23/1,217 (1.9%) patients had a confirmed SCr in-
crease ≥33% from baseline in Months 0 to 3. Four patients
of these 23 patients had SCr values above the reference
range: one patient experienced a serious adverse event
(SAE) of myocardial infarction, but recovered, continued
tofacitinib treatment, and completed the trial; one discon-
tinued due to an AE of dermatitis; and in two patients the
creatinine returned to within normal limits with contin-
ued tofacitinib treatment and they completed the trial
(Figure 1C). Patients with two or more SCr increases
≥33% over baseline generally displayed stable or reduced
levels over the remainder of the Phase 3 studies, despite
continuation of therapy. A total of 16 and 12 tofacitinib-
treated patients permanently discontinued due to SCr in-
creases >50% over baseline in the Phase 3 and LTE (as of
September 29, 2011) studies, respectively.
Shift analyses
Patients demonstrating rises in SCr at the end of the
index study showed no further increase in SCr during
the LTE study (Tables 1 and 2). As shown in Table 1, the
majority of patients who exhibited a >10% increase in
SCr at the EoT in the Phase 3 studies either stayed in
the same category or were in a lower category in the
LTE studies. Similarly, patients who exhibited a >10% in-
crease in SCr at the EoT in Phase 3 had very similar
changes at both the EoT in Phase 3 and LOV in the LTE
(Table 2). Together, these data indicate that patients with
larger changes (>10%) in SCr in the Phase 3 studies did
not demonstrate a further increase in SCr levels in the
LTE studies.
Exposure-response analyses
Analyses of Phase 2 data suggested a dose response in
mean SCr. The final model estimated an ED50 of 0.88 mgTable 1 SCr levels in the LTE and Phase 3 studies: number (pe
in SCr in the LTE studies versus increase at EoT in the Phase
SCr increase at EoT
in Phase 3 (%)
LTE study: maximum perc
≤10% >10 to <33%
≤10% 634 (69.8) 264 (29.0)
>10 to <33% 208 (31.9) 395 (60.5)
≥33 to ≤50% 24 (29.3) 28 (34.2)
>50% 0 (0.0) 2 (28.6)
EoT, end of treatment; LTE, long-term extension; SCr, serum creatinine.suggesting that doses of tofacitinib 5 mg BID and greater
are in excess of the ED80 (3.5 mg). Therefore, similar mean
SCr increases were predicted for the 5 and 10 mg BID
doses in Phase 3 trials.
SCr levels at Month 12 in Phase 3 and in LTE studies
were consistent with predictions at Month 6 from the
Phase 2 double-blind data, suggesting that there was no
evidence of a progressive increase in SCr levels with long-
term treatment. In the A3921019 study, SCr increases
reached steady-state levels in a typical patient by approxi-
mately six weeks and reversed in patients on 5 mg BID
two to six weeks after stopping tofacitinib (Figure 2); the
15 mg and 30 mg BID doses were not carried forward into
Phase 3 studies. In both Phase 3 and LTE studies, SCr
changes were similar between patients receiving tofaciti-
nib plus background DMARDs and those on tofacitinib
monotherapy.
Likelihood ratio tests indicated statistically significant
(P <0.05) effects of baseline CRP on baseline, Emax, and
ED50. Lower baseline SCr values, greater maximum effects
of tofacitinib on SCr (greater Emax), and lower potencies
(higher ED50) were associated with greater baseline CRP
values (Figure 3A). The onset rate of the SCr changes did
not appear to be associated with baseline CRP (that is, ef-
fects of baseline CRP on Kout were not significant).
From the Phase 3 data, it appeared that the higher the
burden of inflammation, as assessed by baseline CRP, the
greater the increase observed in SCr (Figure 3B). A simi-
lar trend was observed with patients treated with adali-
mumab, although the magnitude of SCr increase was
lower than that of tofacitinib. Moreover, patients who
showed the greatest reductions in CRP (quartile 1) fol-
lowing tofacitinib treatment appeared to have the high-
est increases in SCr compared with those who showed
smaller reductions in CRP (quartile 4; Figure 3C). This
trend was seen across all treatment arms, although the
magnitude of increase differed between tofacitinib, adali-
mumab, and placebo. Similar relationships were seen
when CK was analyzed either by quartiles of baseline
CRP or change from baseline CRP at Week 12 (Figure 4A
and B). There was a trend toward greater increases in
SCr in those patients who had greater increases in CK
(Figure 4C).rcentage) of patients with maximum confirmed increase
3 studies
entage confirmed increase in creatinine (n = 1,651)
≥33 to ≤50% >50% Total
9 (1.0) 2 (0.2) 909 (100.0)
43 (6.6) 7 (1.1) 653 (100.0)
24 (29.3) 6 (7.3) 82 (100.0)
2 (28.6) 3 (42.9) 7 (100.0)
Table 2 SCr levels in the LTE and Phase 3 studies: stabilization of SCr levels in the LTE studies
SCr increase at EoT
in Phase 3 (%)
Mean (%) increase from baseline
at EoT in index study, mg/dl
Mean (%) increase from baseline
at last observed visit in LTE, mg/dl
≤10% (n = 909) 0.00 (0.3) 0.05 (7.5)
>10 to <33% (n = 653) 0.13 (18.6) 0.13 (18.5)
≥33 to ≤50% (n = 82) 0.25 (38.2) 0.24 (36.5)
>50% (n = 7) 0.32 (56.0) 0.26 (44.9)
EoT, end of treatment; LTE, long-term extension; SCr, serum creatinine.
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Of 3,030 tofacitinib-treated patients participating in
Phase 3 studies, 0.3 to 0.7% experienced AEs reported as
ARF. In the LTE studies, 2.9% and 1.0% of patients in the
tofacitinib 5 and 10 mg BID groups, respectively, experi-
enced AEs reported as ARF. Across the Phase 3 and LTE
studies, analysis of the 41 ARF AEs identified 22 tofacitinib-
treated patients as having clinical ARF (Figure 5). Of these,
18 patients had a likely prerenal cause such as dehydration,
sepsis, congestive heart failure, or multi-system organ
failure; four patients had an unclear etiology, two of which
were post-study: of these, one patient experienced post-
operative ARF following surgery for metastatic adenocarcin-
oma six weeks post-study, and the other after hip surgery
eight weeks post-study (Additional file 13: Table S1). Of
these 22 patients, six died, 13 resolved, two had ongoing
cases of ARF at the time of the final visit in the LTE studies,
and one improved. One patient receiving placebo died, with
sepsis as a likely prerenal cause (Additional file 13: Table
S1). Concomitant medications, including ACE inhibitors,
ARBs, NSAIDs, and diuretics, were frequently used by pa-
tients with ARF, consistent with use in patients with RA.
Resolution of ARF generally occurred with therapy of the
prerenal contributing factors and temporary or permanentFigure 2 SCr reversibility in a six-week Phase 2 study (A3921019) of tdiscontinuation of tofacitinib. Similar resolution occurred
in those with laboratory test result increases of SCr.
Discussion
Plasma or serum creatinine and its renal clearance are the
most widely used indicators of GFR and thus renal function
and increases in SCr in drug studies are often considered
surrogates for impairment of renal function and clinical
toxicity [11-13]. As SCr is derived from muscle creatine,
factors that impact SCr levels include muscle mass and
muscle turnover (recovery from starvation, muscle disease),
medications, dietary protein, and creatine levels in addition
to glomerular filtration and tubular transport [11-13]. Since
these parameters themselves can vary longitudinally the
relationship between SCr and GFR can change over time
[12]. This is apparent in patients with RA, for example,
where reduced muscle mass, immobilization or reduced
activity, and inflammation, can further complicate the
interpretation of SCr, such that SCr levels are often con-
sidered to be a relatively poor indicator of GFR in this
population [11,13].
No effect of tofacitinib on SCr or measured GFR was
seen in healthy volunteers. Additionally, a study of tofaci-
tinib co-administered with metformin, to assess possibleofacitinib.
Figure 3 Relationships between SCr and CRP using Phase 2 modeling data and Phase 3 data. (A) Relationships between SCr model
parameters and baseline CRP. (B) SCr increases at Month 3 by baseline CRP; baseline CRP Q1 < < Q4. (C) SCr increases at Month 3 by change in
CRP at Month 3; reductions in CRP Q1 > > Q4.
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Figure 4 Relationships between CK and SCr and CRP using Phase 3 data. (A) CK increases at Week 12 by baseline CRP; baseline CRP Q1 << Q4.
(B) CK increases at Month 3 by change in CRP at Month 3; reductions in CRP Q1 > >Q4. (C) SCr increases at Month 3 by change in CK at Month 3;
reductions in CK Q1 > >Q4.
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Figure 5 Evaluation of renal events. Includes all patients coded to the narrow SMQ of ARF or required permanent discontinuation, temporary
discontinuation or dose reduction of the study drug. ARF, acute renal failure; SMQ, Standardized Medical Dictionary for Regulatory Activities Queries.
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porters (OCTs), reported no changes in metformin
systemic exposure or renal clearance in healthy volun-
teers, and thus did not support altered tubular secretion
as a mechanism for tofacitinib-associated changes in SCr
(A3921143; NCT01405118 [23]). Nonetheless, since the
study was not performed in patients with RA, and given
that inflammation affects the expression of trans-
porters and drug-metabolizing enzymes [24], the possibil-
ity of RA interfering with OCT expression, which is then
corrected by tofacitinib, cannot be excluded.
Data on the natural course of SCr changes in patients
with RA and in response to DMARDs other than MTX
or calcineurin inhibitors are limited. In a MTX study,
renal clearance of MTX at six months decreased by a
mean (SD) of 23.8 (40.3) ml/min (P = 0.014) and creatin-
ine clearance (standard formula) decreased by a mean
(SD) of 8.6 ml/min (17.2) (P = 0.033) [25]. In a 24-week
study of tacrolimus (a calcineurin inhibitor) in patients
with RA, SCr elevations ≥40% occurred in 8.7% (6/69),
18.8% (12/64), 28.1% (18/64), and 7% (5/71) of patients
receiving tacrolimus 1 mg, 3 mg, and 5 mg, and placebo
QD, respectively [26]. Measured GFRs were significantly
higher at one year for tofacitinib compared to cyclospor-
ine A in a study of 331 kidney transplant recipients, but
extrapolation to RA is difficult given differences in the pa-
tient population and other factors affecting renal function
in patients posttransplantation [27]. In the tofacitinib RA
program, small increases in SCr were seen with adalimu-
mab but of lesser magnitude than with tofacitinib. To ourknowledge, longitudinal SCr levels in programs of biologic
DMARDs have not been described in detail.
Interestingly, increases in SCr have been reported in pa-
tients with RA treated with other JAK inhibitors in devel-
opment. In a 12-week, Phase 2b, dose-ranging study of
baricitinib (LY3009104), a JAK1/JAK2 inhibitor, in com-
bination with nonbiologic DMARDs, increases in SCr of
0.09 to 0.11 mg/dl (7.96 and 9.72 μmol/l) following two
doses of baricitinib (versus 0.01 mg/dl (0.88 μmol/l) for
placebo) were observed [28]. In a 12-week monotherapy
study of the investigational JAK3 selective inhibitor,
VX-509, increases in SCr across the dose range were re-
ported (0.04 (3.54 μmol/l) versus −0.01 mg/dl (−0.88 μmol/l)
for placebo) [29]. The JAK signaling pathway is utilized
by receptors for interleukins (ILs), interferons (IFNs), and
hormones such as growth hormone and erythropoietin to
mediate intracellular signaling [30]. Inhibition of JAK1
and/or JAK3 by tofacitinib blocks signaling through the
common gamma chain-containing receptors for several cy-
tokines, including IL-2, −4, −7, −9, −15, and −21, as
well as through receptors for cytokines such as IL-6,
IFN-gamma, and type 1 IFN [1]. However, the mechanism
for increases in SCr with JAK inhibitors is not understood.
JAK 1, 2, and 3 have been identified in kidney cells and
tissue, but their role is not defined [31,32]. The available
data do not suggest a deleterious role for JAK inhibition in
renal injury models; JAK inhibitor AG-490 was beneficial in
several renal injury models [33], and JAK inhibitor NC1153
was not nephrotoxic in direct contrast to cyclosporine A in
the low-salt rat model [34]. Tofacitinib was not nephrotoxic
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or urea nitrogen were observed, and no adverse histologic
findings were detected in studies of up to six months in
rats, and nine months in monkeys [9,10]. Systemic expo-
sures, based on area under the plasma concentration versus
time curve for unbound tofacitinib, were up to 188 times in
rats and six times in monkeys compared to that in patients
with RA at a dose of 5 mg BID.
Given that small dose-dependent increases in mean CK
were observed with tofacitinib treatment (and to a lesser
degree with adalimumab) in the Phase 3 clinical program,
we examined the relationship of CRP, as a marker of in-
flammation, with both SCr and CK. Serum CK has been
shown to be lower in patients with RA versus healthy vol-
unteers and to correlate with the level of inflammation [35].
Generally, mean CK tended to plateau after six months of
tofacitinib treatment, stayed within the normal reference
range and was not associated with clinical myopathy or
changes in markers of muscle catabolism (lactate dehydro-
genase and myoglobin). Exploratory analyses revealed an
association between high baseline CRP levels and low
baseline SCr in this RA population. Furthermore, the
higher the CRP, the greater the increases seen in SCr upon
treatment with tofacitinib; similar results were observed
following adalimumab treatment, but of a lesser magni-
tude. A similar relationship was observed between CK and
CRP and patients with greater CK increases also displayed
greater SCr changes.
Taken together, these data suggest that the changes in
SCr observed in the present studies may be related at
least in part to an effect of JAK inhibition on the inflam-
matory burden of RA, possibly secondary to changes in
creatinine generation. A recently completed measured
GFR study in patients with RA receiving tofacitinib or
placebo will provide further information on tofacitinib’s
effect on the kidney (A3921152; NCT01484561).
Clinical manifestations of ARF in the Phase 3 and LTE
studies showed no clear dose association and did not
occur as a result of continuing SCr increases over time,
but occurred acutely, with etiologies consistent with the
causes of ARF in the general population (mostly prerenal -
congestive heart failure, sepsis, or dehydration) [36]. Con-
comitant medications were consistent with those used in
patients with RA. Resolution of ARF occurred in most pa-
tients, usually following treatment of contributing factors
and temporary or permanent discontinuation of study
drug or concomitant medications.
Conclusions
Data summarized here suggest that tofacitinib has a
small and reversible effect on mean SCr in patients with
RA. These changes plateaued and did not appear to be
associated with ARF or progressive worsening of renal
function in the LTE studies. ARF occurred infrequentlywith tofacitinib treatment, was observed in the setting of
concurrent illnesses associated with ARF in the general
population, and generally reversed with appropriate man-
agement including discontinuation of study treatment or
concomitant medications. The mechanism behind the SCr
changes in RA with tofacitinib is presently unknown, and
undergoing further investigation; however, exploratory ana-
lyses suggest a possible link between tofacitinib-induced
changes in inflammation, SCr, and CK.
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